GlaxoSmithKline

Summary

GlaxoSmithKline appeared to be the Corporate Investor, which was created in 1929. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Middlesex.

The higher amount of exits for fund were in 2019. Comparing to the other companies, this GlaxoSmithKline performs on 4 percentage points more the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2015. The real fund results show that this Corporate Investor is 19 percentage points more often commits exit comparing to other companies. When the investment is from GlaxoSmithKline the average startup value is more than 1 billion dollars. The fund is constantly included in less than 2 deals per year.

The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Biopharma, Intellectual Property. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline 23andMe, Genmab, NeuroTherapeutics Pharma

The overall number of key employees were 14.

The typical case for the fund is to invest in rounds with 4 participants. Despite the GlaxoSmithKline, startups are often financed by Three Arch Partners, TVM Capital, Skyline Ventures. The meaningful sponsors for the fund in investment in the same round are SR One, Avalon Ventures, The Kraft Group. In the next rounds fund is usually obtained by Wellington Management, SR One, OUP (Osage University Partners).